Literature DB >> 17400300

Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.

M Angela Cenci1.   

Abstract

The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movement sequences, and its degeneration causes the characteristic motor symptoms of Parkinson's disease. Parkinsonian motor symptoms are alleviated by L-DOPA, but this treatment induces motor fluctuations and dyskinesias (abnormal involuntary movements). Clinical and experimental findings indicate that the motor complications of L-DOPA pharmacotherapy are triggered by transient and large changes in extracellular DA levels. The disruption of presynaptic DA homeostasis sets in motion a cascade of postsynaptic alterations, which prime the brain for a complicated motor response to dopaminomimetic treatment. L-DOPA-induced dyskinesia provides a paradigm to study how the dysregulation of DA release and clearance results in maladaptive neuroplasticity sustaining abnormal patterns of movement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400300     DOI: 10.1016/j.tins.2007.03.005

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  92 in total

1.  Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Authors:  Manfred Gerlach; Jürgen Beck; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2011-01-28       Impact factor: 3.575

2.  The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.

Authors:  Sukju Gil; Changhwan Park; Jeongeun Lee; Hyunchul Koh
Journal:  Cell Mol Neurobiol       Date:  2010-03-16       Impact factor: 5.046

3.  Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates.

Authors:  Arun Singh; Claire A Gutekunst; Subramaniam Uthayathas; John P M Finberg; Klaus Mewes; Robert E Gross; Stella M Papa; Yair Feld
Journal:  Neurosci Bull       Date:  2015-09-15       Impact factor: 5.203

4.  Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.

Authors:  E Grünblatt; W J Schmidt; D K A Scheller; P Riederer; M Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

5.  Levodopa-induced dyskinesia and striatal signaling pathways.

Authors:  Antonio Pisani; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-26       Impact factor: 11.205

6.  Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay Riddle; Suzy A Griffin; Peter Grundt; Amy Hauck Newman; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

7.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

8.  Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

Authors:  Kristin B Dupre; Corinne Y Ostock; Jessica A George; Karen L Eskow Jaunarajs; Cara M Hueston; Christopher Bishop
Journal:  ACS Chem Neurosci       Date:  2013-04-01       Impact factor: 4.418

9.  Loss of laterality in chronic cocaine users: an fMRI investigation of sensorimotor control.

Authors:  Colleen A Hanlon; Michael J Wesley; Alicia J Roth; Mack D Miller; Linda J Porrino
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

10.  α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.

Authors:  Danhui Zhang; Matthew McGregor; Tanuja Bordia; Xiomara A Perez; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2015-11-17       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.